Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Tóm tắt
Từ khóa
Tài liệu tham khảo
James, 2004, The obesity epidemic, metabolic syndrome and future prevention strategies, Eur J Cardiovasc Prev Rehabil, 11, 3, 10.1097/01.hjr.0000114707.27531.48
York, 2004, American Heart Association. Prevention conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity, Circulation, 110, e463, 10.1161/01.CIR.0000140125.26161.49
2002
Cota, 2003, The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis, J Clin Invest, 112, 423, 10.1172/JCI17725
Di Marzo, 2004, The endocannabinoid system and its therapeutic exploitation, Nat Rev Drug Discov, 3, 771, 10.1038/nrd1495
Di Marzo, 2001, Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature, 410, 822, 10.1038/35071088
Croci, 1998, In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum, Br J Pharmacol, 125, 1393, 10.1038/sj.bjp.0702190
Bensaid, 2003, The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells, Mol Pharmacol, 63, 908, 10.1124/mol.63.4.908
Howlett, 2004, Cannabinoid physiology and pharmacology: 30 years of progress, Neuropharmacology, 47, 345, 10.1016/j.neuropharm.2004.07.030
Ravinet Trillou, 2003, Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, Am J Physiol Regul Integr Comp Physiol, 284, R345, 10.1152/ajpregu.00545.2002
Gomez, 2002, A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding, J Neurosci, 22, 9612, 10.1523/JNEUROSCI.22-21-09612.2002
Kirkham, 2003, Endogenous cannabinoids: a new target in the treatment of obesity, Am J Physiol Regul Integr Comp Physiol, 284, R343, 10.1152/ajpregu.00706.2002
Horvath, 2003, Endocannabinoids and the regulation of body fat: the smoke is clearing, J Clin Invest, 112, 323, 10.1172/JCI19376
Kunos, 2001, Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice, Neurochem Res, 26, 1015, 10.1023/A:1012301021419
Cota, 2003, Endogenous cannabinoid system as a modulator of food intake, Int J Obes Relat Metab Disord, 27, 289, 10.1038/sj.ijo.0802250
1996
2002, Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143
Matthews, 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883
Zigmond, 1983, The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x
Goldstein, 1992, Beneficial health effects of modest weight loss, Int J Obes Relat Metab Disord, 16, 397
Van Gaal, 1997, The beneficial effects of modest weight loss on cardiovascular risk factors, Int J Obes Relat Metab Disord, 21, S5
Zhu, 2002, Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds, Am J Clin Nutr, 76, 743, 10.1093/ajcn/76.4.743
Janssen, 2004, Waist circumference and not body mass index explains obesity-related health risk, Am J Clin Nutr, 79, 379, 10.1093/ajcn/79.3.379
Després, 2001, Treatment of obesity: need to focus on high risk abdominally obese patients, BMJ, 322, 716, 10.1136/bmj.322.7288.716
Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8
Matsuda, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561, 10.1038/346561a0
Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61, 10.1038/365061a0
Howlett, 2002, The cannabinoid receptors, Prostaglandins Other Lipid Mediat, 68–69, 619, 10.1016/S0090-6980(02)00060-6
Petrocellis, 2004, The endocannabinoid system: a general view and latest additions, Br J Pharmacol, 141, 765, 10.1038/sj.bjp.0705666
Liu, 2004, Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice, Int J Obes Relat Metab Disord, 29, 183, 10.1038/sj.ijo.0802847
Arnone, 1997, Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacology (Berl), 132, 104, 10.1007/s002130050326
Simiand, 1998, SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset, Behav Pharmacol, 9, 179
Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992
Combs, 2001, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, J Clin Invest, 108, 1875, 10.1172/JCI14120
Fruebis, 2001, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc Natl Acad Sci USA, 98, 2005, 10.1073/pnas.98.4.2005
Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 7, 941, 10.1038/90984
Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9
Meigs, 2003, Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies, Diabetes, 52, 2160, 10.2337/diabetes.52.8.2160